Loading
A phase 2 trial in lung cancer, run by Alliance Foundation Trials, LLC., now recruiting.
Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer is a phase 2, interventional study registered as NCT07149363 by Alliance Foundation Trials, LLC., with a registry enrolment figure of 65 participants, started 2026-02-12 and due to reach its primary completion in 2029-02. Interventions recorded: Durvalumab 50 MG/ML. Conditions listed: Small Cell Lung Cancer (SCLC). Primary outcome: Disease free survival (DFS). Lung eligibility wording from the registry: "* Must have histologically or cytologically confirmed diagnosis of pathologic T1-T2 N0-1 M0 small-cell lung cancer per the American Joint Committee on Cancer staging system, 8th edition". Sites: United States. No results are recorded here; the registry entry is the source.
Shares Lung cancer trials open today (registry snapshot), AstraZeneca and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), AstraZeneca and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), AstraZeneca and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), AstraZeneca and the tag lung-deep-dive.